Well, you rely on some journalists for your short thesis. I prefer to look at the caliber of the institutional investors who have place large "long" $$ here, along with the analysts covering the stock ... Reiterations of buys and raised price targets. In addition, the contracts being signed are with the top echelon of pharma. Still like my risk reward!!
Also, the only negative "reports" are the SA articles, not any analyst coverage. So, I suggest you take THAT with a grain of salt, too!
It goes both ways ... I can appreciate some skepticism. However, if you put the puzzle pieces together (the string of signed agreements/deals coming in), you certainly have to see an improved picture, no?
Or, let's do the math for our short "experts" ... that's over 200% increase! I like the risk/reward!
Have a good weekend!
UNIS - Griffin Securities Re-iterates Buy Target price 10.50
So, they're upping their Sept. target of $10.50 by 30%? Nice!
"We" don't need instant gratification and most of us have decided not to feed the trolls. I was bored so I took you off ignore ... big mistake, you're even more boring! Buh bye!!
Making too much of it, imo. Lots of biotechs are weak today and have been all week. Shorts probably shorted more on the spike and will be covering down here. That's the way of biotechs ... they spike on news and then as euphoria fades, the shorts take retail $$. Accumulate and take a little profit into the spikes. There WILL be some ... news is coming.
Was wondering how others felt about being paid in cash or stock. I was torn .. thanks for sharing! And, I agree the market isn't placing enough value on being cash flow positive and NO debt for a biotech company. I'm accumulating as I can under $15.
It's Phase I, and they didn't have the greatest luck with it with breast cancer in further studies. Still ... I took at flier at it at $5.78 for a trade off of the conference update next week.
Bad call on OCLS for you right now.
And we are still be kicked to the curb ... there are dark forces "afoot" here, imo. I trust mgmt. has an ace up their sleeve. They are aware of the shenanigans.
Thanks for staying positive Oz!!
Got them at $3.50ish and sold them for $10. Probably some walking around $$ and cash to pay the taxes. No biggie!
Has to do with similar drug not getting NCE approval, so AF says KERX won't either, I think.
Still say look at the investor base ... as for flustered, it has more to do with time constraints in that type of presentation. But, you say tomato and I say tomAto.
If you want a well capitalized stem company, look at OSIR. Weird situation, really. Small float, very TIGHT insider ownership, no debt, just went cash flow positive. Can't cut a break in the media which, I think, is due to naked shorting. When they get positive news, it flies ... and then google "Dalton man regrows foot"! Exciting stuff! Been in it since $6s.